| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA753: Cenobamate for focal onset seizures in epilepsy |
|
Medicine details |
|
| Medicine name | cenobamate (Ontozry®) |
| Formulation | 12.5mg, 25mg, 50mg ,100mg, 150mg, 200mg film-coated tablets |
| Reference number | 3915 |
| Indication | Adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products |
| Company | Arvelle Therapeutics |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/02/2021 |
| NICE guidance | |